REVIEW Metoprolol succinate is the extended-release formulation of the active substance metoprolol, a selective beta1 receptor blocker used in treatment of several cardiovascular diseases. It is used for a number of conditions including hypertension, angina, acute myocardial infarction, supraventricular tachycardia, ventricular tachycardia, congestive heart failure, and prevention of migraine headaches. Metoprolol competes with adrenergic neurotransmitters such as catecholamines for binding at cardiac beta1 receptors, resulting in a decrease in heart rate, cardiac output, and blood pressure. Due to its selectivity for cardiac beta1 receptors, metoprolol is also prescribed for anxiety disorders.
Mehra, Janakraj Karamchand; Choubey, Ajit; Srivastava, Bimal Kumar; Porwal, Rajendra Kumar; Gautam, Prashant Metoprolol manufacturing process from 4-(2-methoxyethyl)phenol and epichlorhydrin U.S. Pat. Appl. Publ. (2005), US 20050107635 A1 20050519.
Arnalot Aguilar, Carmen; Bosch i Llado, Jordi Process for preparation of metoprolol from 4-(2-methoxyethyl)phenol, epichlorohydrin, and isopropylamine. PCT Int. Appl. (2007), WO 2007141593 A2 20071213.
'D''Souza, Valerian M.; Ghogare, Anil B Process of making dicarboxylic salts of metoprolol PCT Int. Appl. (2010), WO 2010058407 A2 20100527.'
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 1999 Jun 12;353(9169):2001-7.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.